在一项前瞻性试验（A5170）中，HIV 中和抗体与治疗中断后较低的病毒载量相关。
Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).
出版信息
AIDS. 2012 Jul 17;26(11):1452. doi: 10.1097/QAD.0b013e3283550b8e.
OBJECTIVE
We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a cohort of HAART recipients who underwent extended structured treatment interruption.
DESIGN
Substudy of NAb in the AIDS Clinical Trials Group 5170 trial.
METHODS
Early plasma samples from 50 volunteers who discontinued HAART were evaluated in a peripheral blood mononuclear cell-based neutralization assay against a panel of four subtype B primary isolates.
RESULTS
We found that high-titer (90% inhibitory dose > 500) NAb against two or more isolates was associated with reduced viral load (=0.003 at 12-week posttreatment interruption). This effect faded with time, losing significance (=0.161) by study conclusion. Participants possessing the highest NAb levels against individual isolates appeared more likely to have lower viral loads with the association gaining significance against the R5-tropic primary isolate US1 (=0.005). There was no association between broader neutralization and CD4 T-cell slope over time.
CONCLUSION
The data suggest that high-titer NAb responses at the time of treatment interruption are associated with reduced viral load over time, but not CD4 T-cell decline.
目的
我们研究了中和抗体（NAb）对接受延长时间结构性治疗中断的抗逆转录病毒治疗（HAART）受者的 CD4 T 细胞计数和病毒载量的影响。
设计
艾滋病临床试验组 5170 试验中 NAb 的子研究。
方法
对 50 名停止 HAART 的志愿者的早期血浆样本进行了基于外周血单核细胞的中和测定，以评估对四个 B 亚型原发性分离物的面板的中和能力。
结果
我们发现，针对两种或多种分离物的高滴度（90%抑制剂量>500）NAb 与病毒载量降低有关（治疗中断后 12 周时=0.003）。这种效应随着时间的推移而减弱，在研究结束时失去了显著性（=0.161）。针对个体分离物具有最高 NAb 水平的参与者似乎更有可能具有较低的病毒载量，与 R5 嗜性原发性分离物 US1 的关联具有显著性（=0.005）。广泛中和与 CD4 T 细胞斜率之间没有关联。
结论
数据表明，治疗中断时高滴度 NAb 反应与随时间推移病毒载量降低有关，但与 CD4 T 细胞下降无关。
Zotero 插件